Thelansis

  Systemic amyloidosis (SA) encompasses a group of rare disorders characterized by the deposition of misfolded protein aggregates as insoluble fibrils within tissues, resulting in progressive organ dysfunction, disability, and potentially fatal outcomes. Fourteen proteins have been identified as potential etiological agents of SA, with precise identification crucial for targeted therapy specific to each disease subtype. The second most prevalent subtype is transthyretin amyloid protein (ATTR) amyloidosis, which includes both variant ATTR (ATTRv) and wild-type ATTR (ATTRwt). Other less common subtypes include serum amyloid A (AA) amyloidosis, whose incidence is declining due to improved treatment of underlying chronic inflammatory conditions and other hereditary and acquired forms. SA predominantly affects the heart, kidneys, and peripheral and autonomic nervous systems but can also involve other organs, leading to a broad spectrum of clinical syndromes. The nonspecific nature of its